

North West GLH Genomics Tumour Advisory Board (GTAB) and multidisciplinary team (MDT) meetings



To assist with interpretation of genomic reports for cancer patients, the North West Genomics Laboratory Hub (GLH) is offering support through several advisory board meetings. We encourage referrals for discussion where clinical teams may be uncertain about interpretation of a result e.g. regarding treatment selection, clinical trial opportunities, how to approach potential germline findings or for general education and upskilling.

The scope and timings of the different meetings are described below. If you have a case to discuss, please complete the [GLH GTAB referral form](#) and email to: mdt-coordinators.nwglh@mft.nhs.uk. The GLH will triage to the most appropriate forum. Please note, some cases may need discussion in more than one meeting.

ctDNA GTAB

2nd Friday of the month @ 12:00pm & 4th Thursday of the month @ 12:30pm

For discussion of queries regarding circulating tumour DNA (ctDNA) reports, variant interpretation and actionability. Attended by scientific and clinical personnel from the GLH and open to all clinical staff to attend. For ctDNA specific queries, please email mft.northwest.ctdna@nhs.net

Inherited Cancer MDT

1st Tuesday of the month @ 11:00am

For discussion of some potential germline findings* in potentially actionable cancer predisposition genes. where VAF is high (generally >30%). Attended by clinical geneticists (Manchester & Liverpool Clinical Genetics) and NWGLH scientific/clinical staff. Advice will be given on whether confirmatory germline testing is required or if referral to clinical genetics is indicated. This may be required to access clinical genetics services in these cases. Direct referrals to clinical genetics may be re-routed through this meeting.

WGS GTAB

1st Thursday of the month @ 12:30pm & 3rd Friday of the month @ 12:00pm

For discussion regarding whole genome sequencing (WGS) results. Attended by scientific/clinical personnel from the GLH and open to all clinical staff to attend. GLH will guide on which cases should be discussed.

If a case is referred to any of the meetings, attendance from a member of the clinical team is strongly encouraged to clearly present the case and ensure any outcomes can be actioned and recorded in patient EPRs.

